Startups
Helsinn Group
Edit

Helsinn Group

Trusted
http://www.helsinn.com/
Last activity: 25.06.2026
Active
Categories: AppB2BCareHealthTechIndustryInvestmentMarketMedtechOnlineWebsite
Welcome! Thank you for connecting to Helsinn’s LinkedIn profile.
Helsinn would like to emphasize and make you aware that due to the highly regulated nature of the pharma industry, we cannot engage with you online in sensitive discussions or topics concerning our or other companies’ products and/or services, and/or treatment options. It is best to hold such discussions and to seek guidance privately from your healthcare professional.

Helsinn is a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, thanks to a consolidated track record, a solid revenue stream in B2B and strong cash flow and cash position.

Since 1976, Helsinn has been improving the lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model, and by collaborating with success in about 190 countries with long-standing partners who share our values.

If you are interested in joining Helsinn Healthcare or one of our affiliates, please visit the following website: helsinn.com. If you are interested in applying for an open position, please submit your application only through the appropriate country portal you will find in the website under “Working for Helsinn”. Any other sources of communications are unauthorized, and we discourage candidates from replying to suspect employment offers received through unofficial channels. If you are experiencing problems or have questions, please contact for Switzerland [email protected], for the U.S. [email protected], for Ireland [email protected]. [These emails are NOT an application channel: CVs and sensitive information sent inappropriately to the above emails will NOT be considered or processed, and will be DELETED]
Followers
685
Followers
13.09K
Mentions
45

Overview

Location
Switzerland, Ticino, Pazzallo
Employees
501-1000
Founded date
1976

Mentions in press and media 45

DateTitleDescription
Sign up to seeSign up to seeSign up to see
May 11, 2026AnaCardio Announces Phase 1b/2a GOAL-HF1 Results of AC01 Demonstrating Favorable Safety and Sustained Improvements in Cardiac Function on Top of Standard-of-Care Therapy in HFrEFAnaCardio Announces Phase 1b/2a GOAL-HF1 Results of AC01 Demonstrating Favorable Safety and Sustained Improvements in Cardiac Function on Top of Standard-of-Care Therapy in HFrEF Mon, May 11, 2026 08:00 CET Report this content STOCKHOLM, Sw...
Mar 26, 2026AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 CongressAnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress Thu, Mar 26, 2026 08:00 CET Report this content STOCKHOLM, Sweden – March 26, 2026 – AnaCardio today announces that ...
Mar 11, 2026AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040sAnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s Wed, Mar 11, 2026 09:00 CET Report this content Stockholm, Sweden and Lugano, Switzerland, March 11, 2026 - AnaCardio, a clinical-stage biopharmac...
Feb 27, 2026InVirtuoLabs closes R&D agreement with Helsinn Under the terms of the agreement, Helsinn will provide InVirtuoLabs with access to a proprietary library of structurally diverse compounds, including validated hits with confirmed biological activity against an undisclosed therapeutic targ...
Dec 10, 2025AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2bAnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b Wed, Dec 10, 2025 08:00 CET Report this content December 10, 2...
Sep 16, 2025AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025 Tue, Sep 16, 2025 09:00 CET Report this content Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-sta...
Sep 2, 2025AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial OfficerAnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer Tue, Sep 02, 2025 09:00 CET Report this content Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutica...
Jul 17, 2025AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEFAnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF Thu, Jul 17, 2025 09:00 CET Report this content Alignment reached with both the FDA and EMA ...
Mar 13, 2025AnaCardio receives patent grant in Europe for AC01AnaCardio receives patent grant in Europe for AC01 Thu, Mar 13, 2025 09:00 CET Report this content Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractil...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Helsinn Group

When was Helsinn Group founded?

Helsinn Group was founded in 1976.

Is Helsinn Group still active?

Yes, Helsinn Group is active; its latest activity on Parsers VC dates from Jun 25, 2026.